NCT02821494View on ClinicalTrials.gov

Hespecta Vaccination in HPV+ Tumors or Malignant Lesions

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

March 31, 2020

Study Completion Date

March 31, 2020

Conditions
Tumors or Premalignant Lesions
Interventions
BIOLOGICAL

Hespecta

A dose escalation of Amplivant® conjugated peptide

Trial Locations (1)

2333 ZA

Leiden University Medical Center, Leiden

Sponsors

Collaborators (1)

ISA Pharmaceuticals
All Listed Sponsors
collaborator

ISA Pharmaceuticals

INDUSTRY

collaborator

Dutch Cancer Society

OTHER

collaborator

Top Institute Pharma

OTHER

lead

Leiden University

OTHER

NCT02821494 - Hespecta Vaccination in HPV+ Tumors or Malignant Lesions | Biotech Hunter | Biotech Hunter